News & Updates
Filter by Specialty:

Mevrometostat plus enzalutamide improves outcomes in mCRPC patients
27 Feb 2025
byStephen Padilla
Treatment with mevrometostat (MEV), an enhancer of zeste homolog 2 inhibitor, in combination with enzalutamide (ENZ) results in better survival outcomes and response than ENZ alone among patients with metastatic castration-resistant prostate cancer (mCRPC), reports a study presented at ASCO GU 2025. The combined therapy also demonstrates a favourable safety profile.